News

The Anticancer Fund champions drug repurposing for cancer at the #iDR24 conference, taking place on March 6 and 7, 2024 in Barcelona. Identifying new uses for existing medicines, represents a significative opportunity for cancer patients.

We present the initial findings of the French-Belgian Metro-PD1 study testing a treatment with nivolumab in combination with metronomic chemotherapy in children and adolescents with relapsing/refractory solid tumours. The study reveals new possible treatment avenues for paediatric solid tumours. The results were published in the European Journal of Cancer.

Ahead of World Cancer Day, we highlight the impact My Cancer Navigator has had in the last five years. Our free information service has been a pillar of support for cancer patients globally.

The Anticancer Fund is excited to announce a groundbreaking collaboration aimed at advancing the field of rare cancer research, the ATTRACT-initiative. In a pioneering effort, five anti-cancer charities will dedicate 21 million euros to accelerate drug development for rare cancers through cross-border clinical academic research.

My Cancer Navigator takes center stage in a podcast produced by Delphine Rémy, renowned for her work on ‘Naître princesse, devenir guerrière’. The podcast delves into the core features and benefits of our information service for cancer patients. Listeners will hear from Gilles Van der Spek, who candidly shares his journey and highlights the impact My Cancer Navigator has had on his experience.

Patients with Acute Myeloid Leukemia (AML) have very few treatment options when the initial chemotherapy has failed. This is particularly true for patients over 60, or with co-morbidities, who are not eligible for stem cell transplantation. On average, they will survive only a few months.

The results of the AML-ViVA trial show that low dose azacitidine, pioglitazone and all-trans retinoic acid is safe in patients who do not respond to initial chemotherapy.